Business Wire

VESTIGO

1.7.2021 09:02:13 CEST | Business Wire | Press release

Share
Cornèr Bank Group Completes Migration of 2.1m Cards to Vestigo’s Card Management Solution

Cornèr Bank Group, issuer of credit and prepaid cards to private individuals and businesses in Europe, has reached a major milestone in its digital transformation journey by completing migration of its card portfolios across all products and markets to a modern, consolidated solution. Vestigo is a European software provider in cards and account-to-account payments space, and its card management system (CMS) is the key component of the overall solution at Cornèr.

Cornèr Bank Group issues more than /2.1/ million credit and prepaid, Visa, Mastercard and Diners cards directly and through partnerships with hundreds of organizations of various sizes in a B2B2C / co-brand business model. The new solution, managed in-house on a single instance, will further improve innovation and quality of service to Cornèr Bank Group’s partners and ultimate cardholders, as well as enhance internal efficiency. Vestigo’s integrated, modular, “multi-everything” solution is fully customer centric, can manage all types of cards, as well as account-to-account payments, and allows for easy integration leveraging 200+ APIs.

This large-scale implementation and migration project was designed to minimize risk and consisted of multiple phases taking into account requirements regarding different markets, products and legacy systems.

Ing. Vittorio Cornaro, Chief Executive Officer of Cornèr Bank Group, said: “Partnering with a trusted partner like Vestigo helps us modernize and consolidate our pan-European card business, which is the key step of our strategy to transform Cornèr into an agile bank delighting our clients and partners every day with best-in-class products and services”

Simone Tettamanti, CIO at Cornèr Banca, added: This complex, large-scale project was an excellent example of two organizations working together successfully as trusted partners towards a common goal, using agile approach. This modern platform will facilitate Cornèr’s business growth and provide us with flexibility to adjust to evolving customer requirements in the future.”

Kata Kamenski, Chief Executive Officer and Co-founder of Vestigo said: “We’re incredibly proud to work with Cornèr, as this further validates Vestigo’s functionality fit, as well as delivery ability fit with sophisticated, innovative financial institutions. Vestigo continues growing strongly, driven by its differentiating capability to drive convergence across cards and account-to-account payments. Our solution is scalable and can be deployed as on-prem, cloud installation or SaaS.”

About Cornèr Bank Group

Founded in Lugano in 1952, the Cornèr Bank Group is an independent Swiss private bank group operating as a full-service bank. Lugano is Switzerland’s third-largest banking centre, after Zurich and Geneva. Active across the whole range of traditional banking services, the Cornèr Bank Group specializes in the private banking sector, as well as in the areas of lending, Visa, Mastercard and Diners Club payment cards (Cornèrcard) and online trading (Cornèrtrader) – the core businesses on which the growth of the Cornèr Bank Group is based. The Cornèr Bank Group comprises the Lugano-based parent bank Cornèr Bank Ltd., the four branches in Chiasso, Geneva, Locarno and Zurich, the branch BonusCard and the affiliates Cornèr Bank (Overseas) Limited, Cornèrcard UK Ltd., Cornèr Europe AG, Diners Club Italia S.r.l. and Dinit d.o.o.

For more information on Cornèr please visit: www.cornergroup.ch

About Vestigo

Vestigo is a founder-owned paytech, fully focused on cards (CMS) and account-to-account payments (PaymentsHub) space. Vestigo’s newest module HolisticPay is a rich payments modernization & convergence layer designed to facilitate managed cards & payments modernization. Our continuously increasing team has more than 130 employees. Vestigo’s modern, modular, customer-centric solution creates value for financial institution clients in payments, issuing and acquiring businesses. We differentiate by bringing the cards and account payments together in a fully customer centric way using modern technology. Vestigo currently supports clients in 7 European countries, with a strong growth strategy into further markets.

For more information on Vestigo please visit: www.vestigo.hr

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye